Netupitant-Palonosetron FDC Market - Global Opportunity Analysis and Industry Forecast to 2022 - Key Players are Helsinn Holding, Heron Therapeutics, Eisai Pharmaceutical & Tesaro - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Netupitant-Palonosetron FDC Market - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering.

The fixed dose combination (FDC) of netupitant and palonosetron is a product proposed for the treatment of the most common side effects of chemotherapy-nausea and vomiting. The product is currently in its third stage of trial. Netupitant is a novel and a NK1 receptor antagonist, and palonosetron is a second-generation 5-HT3 receptor antagonist. While netupitant was not available in the drug market earlier, palonosetron drugs were already present under trade names Paloxi, Onicit, and Aloxi. The combination drug is expected to overcome major problems associated with the current mode of treatment of the CINV condition, which involves the use of 5-HT3 receptor antagonists.

The netupitant-palonosetron FDC market is driven by rise in number of patients who undergo chemotherapy. The market is segmented on the basis of patient pool and geography. Currently, pharmaceutical companies are increasingly investing in the further discovery of FDC drugs to achieve increased industry leading breadth and depth of clinical research.

However, factors such as adverse effect of netupitant-palonosetron FDC and high cost of drugs for patients act as restraints for the growth and development of the market. The new approaches and advancement in netupitant-palonosetron FDC market is the development in efficacy and potential of new FDC drugs. The foundation of combination therapy is projected to build up in broad spectrum. Netupitant-palonosetron, by trade name of Akynzeo, is approved and witnesses an increasing traction in the U.S. and European region.

Companies Mentioned

  • Eisai Pharmaceutical Pvt. Ltd.
  • Helsinn Holding S.A.
  • Heron Therapeutics Inc.
  • Tesaro Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Chapter 4 World Netupitant-Palonosetron Fdc Market, By Patient Pool Type

Chapter 5 World Netupitant-Palonosetron Fdc Market, By Geography

For more information about this report visit http://www.researchandmarkets.com/research/mkvxl4/netupitantpalonos

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs